TLIS: Talis Biomedical Corporation EV/EBITDA Multiple

Talis Biomedical is expanding its network of partnerships with laboratory centers to implement rapid diagnostic systems. Talis Biomedical relies on the Talis One platform, which enables high-precision molecular assays directly within the clinic. This market valuation chart for the company on GURU.Markets reflects a value of , however, the current business status is critical due to delisting and a complete cessation of operational activities.

Talis Biomedical Corp - TLIS Enterprise Value to EBITDA Ratio (period 07/04/2022 - 11/10/2026)

Summary analytical data breakdowns for talis.bio (TLIS)

- stock price and consensus target price:

Stock Quotes Talis Biomedical Corporation|TLIS - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Talis Biomedical Corporation|TLIS - Company Buyout Price

- issuer book value statistics:

Book Value per Share Talis Biomedical|TLIS - Company Net Assets|Market Cap to Net Assets Ratio talis.bio|TLIS - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

TLIS - Net Income|Projected Future Earnings Talis Biomedical|TLIS - P/E Multiple|Future Price to Earnings Talis Biomedical Corporation|TLIS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Talis Biomedical Corporation|TLIS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Talis Biomedical|TLIS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months talis.bio|TLIS - Net earnings per share change in current year|Expected earnings per share growth for next year Talis Biomedical

Initial company analysis:Talis Biomedical Corp TLIS

This multiple compares the total business value, including net debt, with its ability to generate cash flow before taxes and depreciation. An analysis of the enterprise value to EBITDA ratio allows for the determination of the real value of assets relative to their operational efficiency. For Talis Biomedical (TLIS), this indicator is critical, as it reflects the risk of capital loss amid workforce reductions and the mothballing of core capacities.

Competitor analysis for Talis Biomedical

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hyperfine, Inc. HYPR|fonar.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DXR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MDAI (spectral-ai.com)|VIVS: EV/EBITDA Multiple|Company Value to EBITDA Aclarion Corporation (ACON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akoya Biosciences Inc|THMO - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)